186386-91-4

Upstream product

• 75-89-8 2,2,2-trifluoroethanol 
• 446-35-5 2,4-Difluoronitrobenzene 
• 446-36-6 5-fluoro-2-nitrophenol 
• 6226-25-1 2,2,2-trifluoroethyl trifluoromethanesulphonate 

Downstream Products

• 1168134-09-5 2-[4-amino-3-bromo-5-(2,2,2-trifluoroethoxy)phenyl]-3-cyclobutylpropionic acid methyl ester 
• 1168134-08-4 2-[4-amino-3-(2,2,2-trifluoroethoxy)phenyl]-3-cyclobutylpropionic acid methyl ester 
• 1168134-07-3 3-cyclobutyl-2-[4-nitro-3-(2,2,2-trifluoroethoxy)phenyl]propionic acid methyl ester 
• 1168134-06-2 [4-nitro-3-(2,2,2-trifluoroethoxy)phenyl]acetic acid methyl ester 
• 1168134-05-1 2-[4-nitro-3-(2,2,2-trifluoroethoxy)phenyl]acetic acid 
• 1301761-77-2 2-fluoro-N-methyl-5-nitro-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonamide 
• 1094470-95-7 2-fluoro-5-nitro-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonyl chloride 
• 1301761-78-3 5-amino-2-fluoro-N-methyl-4-[(2,2,2-trifluoroethyl)oxy]benzenesulfonamide 
• 186386-21-0 RS 100975 
• 186388-11-4 1-(3-chloro-propyl)-4-[4-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazine 
• 186387-05-3 1-[4-fluoro-2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 
• 186386-90-3 4-fluoro-2-(2,2,2-trifluoroethoxy)aniline 

Relevant academic research and scientific papers

AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS

The present invention relates to 2,4-diaminopyrimidines and pharmaceutically acceptable salts thereof, purification methods for the same, pharmaceutical compositions containing them, methods of obtaining and using them for the treatment of disease states,

TETRASUBSTITUTED BENZENES FOR TREATMENT OF EARLY ONSET ALZHEIMER'S DISEASE

Provided are compositions and methods for treating early onset familial Alzheimer's Disease. The compositions and methods can be used for improving one or more aspects of cognitive function in a patient suffering from early onset familial Alzheimer's Dise

QUINAZOLINE COMPOUNDS

Disclosed are compounds having the formula: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, and methods of making and using the same.

COMPOUNDS AND METHODS

Disclosed are compounds having the formula (I): wherein R1, R2, R3, R4, R5, and R6 are as defined herein, and methods of making and using the same.

TETRASUBSTITUTED BENZENES

Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

SUBSTITUTED ISOQUINOLINONES

Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

Synthesis, pharmacology and pharmacokinetics of 3-(4-Arylpiperazin-1-ylalkyl)-uracils as uroselective α1A-antagonists

Predominance in the urethra and prostate of the α1A-adrenoceptor subtype, which is believed to be the receptor mediating noradrenaline induced smooth muscle contraction in these tissues, led to the preparation of α1A-selective antagonists to be tested as uroselective compounds for the treatment of benign prostatic hyperplasia. Thus, a number of selective α1A-adrenoceptor antagonists were synthesized and assayed in vitro for potency and selectivity. Dog pharmacokinetic parameters of 12 (RO700004) and its metabolite 40 (RO1104253) were established. The relative selectivity of intravenously administered 12, 40 and standard prazosin to inhibit hypogastric nerve stimulation-induced increases in intraurethral prostatic pressure versus phenylephrine-induced increases in diastolic blood pressure in anesthetized dogs was 76, 71 and 0.6, respectively.

PYRIMIDINEDIONE, PYRIMIDINETRIONE, TRIAZINEDIONE AND TETRAHYDROQUINAZOLINEDIONE DERIVATIVES AS ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS

Compounds of Formula I: STR1 where R 5 is a group selected from Formulae (a), (b), (c) and (d): STR2 and the pharmaceutically acceptable salts and N-oxides thereof, are α 1-adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.